Dai­ichi Sankyo scraps ear­ly-stage ADC pro­gram in gas­troin­testi­nal tu­mors af­ter first phase fail

Dri­ven by a se­ries of wins for its an­ti­body-drug con­ju­gate pipeline, Dai­ichi Sankyo has earned a rep­u­ta­tion as an ADC ex­pert with a suc­cess­ful part­ner­ship with As­traZeneca un­der its belt. But fail­ures do hap­pen — and for Dai­ichi, it’s where the com­pa­ny least ex­pect­ed it.

Dai­ichi has scrapped de­vel­op­ment of DS-6157, an ADC tar­get­ing the GPR20 pro­tein in gas­troin­testi­nal stro­mal tu­mors (GIST), af­ter the drug failed a Phase I test, the drug­mak­er re­vealed in its Q2 up­date Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER